GRAFAPEX- treosulfan injection, powder, lyophilized, for solution

GRAFAPEX by

Drug Labeling and Warnings

GRAFAPEX by is a Prescription medication manufactured, distributed, or labeled by Medexus Pharma, Inc., Oncotec Pharma Produktion GmbH. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: MYELOSUPPRESSION

    • GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage.
    • Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters[see Warnings and Precautions ( 5.1)] .
  • 1 INDICATIONS AND USAGE

    1.1 Acute Myeloid Leukemia

    GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML).

    1.2 Myelodysplastic Syndrome

    GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS).

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage

    The recommended dosage of GRAFAPEX is 10 g/m 2by intravenous infusion given daily for three days, beginning on Day -4 prior to transplantation in combination with fludarabine as outlined in Table 1.

    Table 1: Dosage Regimen for GRAFAPEX-Based Allogeneic HSCT
    TreatmentDay -6Day -5Day -4 Day-3Day -2Day -1Day 0

    GRAFAPEX 10 g/m 2/day intravenous infusion

    X

    X

    X

    Fludarabine 30 mg/m 2/day intravenous infusion

    X

    X

    X

    X

    X

    Allogeneic hematopoietic stem cell infusion

    X

    Premedicate patients with antiemetics prior to the first dose of GRAFAPEX and continue antiemetics on a fixed schedule through completion of treosulfan administration.

    2.2 Preparation and Administration Instructions

    Reconstitute GRAFAPEX prior to intravenous infusion.

    GRAFAPEX is a hazardous drug. Follow applicable special handling and disposal procedures. 1

    • Use aseptic technique to prepare GRAFAPEX.
    • Calculate the dose, the total volume of reconstituted GRAFAPEX solution required, and the number of GRAFAPEX vials needed.
    • Reconstitute each vial with 0.45% Sodium Chloride Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or Sterile Water for Injection, in its original glass container using volumes described in Table 2 to obtain a final concentration of approximately 0.05 g/mL of GRAFAPEX. Reconstitution with Sterile Water for Injection alone is not recommended in children less than or equal to 12 years of age due to the resulting hypo-osmolarity of the final solution.
    Table 2: Reconstitution Solution Volume
    StrengthVolume

    1 g/vial

    20 mL

    5 g/vial

    100 mL
    • Shake the vial(s) to dissolve.
    • Inspect the reconstituted solution for discoloration and particulate matter. The reconstituted solution appears as a clear colorless solution. Solutions showing any sign of precipitation should not be used. In case that solubility issues occur, prolonged standing time or slight warming of the reconstituted solution (hand warm) may be useful.
    • Determine the volume of 0.05 g/mL reconstituted solution needed based on the required dose. Reconstituted solutions of GRAFAPEX may be combined into a larger glass vial, ethylene-vinyl acetate (EVA) bag or polyolefin (PO) bag. Discard any unused portion left in the vial(s).

    If not used immediately store reconstituted GRAFAPEX solution at room temperature 20°C to 25°C (68°F to 77°F) for up to 24 hours. Do not use if the solution contains a precipitate.

    Do not refrigerate.

    Infuse GRAFAPEX intravenously over 2 hours. Confirm patency of the intravenous line prior to infusion. Monitor for extravasation; if extravasation occurs, stop the infusion  [see Warnings and Precautions ( 5.4)] .

  • 3 DOSAGE FORMS AND STRENGTHS

    For injection: 1 g/vial or 5 g/vial treosulfan as a white, sterile, lyophilized powder in single-dose vials for reconstitution.

  • 4 CONTRAINDICATIONS

    GRAFAPEX is contraindicated in patients with hypersensitivity to any component of the drug product.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Myelosuppression

    Profound myelosuppression with pancytopenia is the desired therapeutic effect of GRAFAPEX-based preparative regimens, occurring in all patients. Time to neutrophil counts > 0.5 Gi/L occurred at a median of 18 days (range 7-42 days) after allogeneic hematopoietic stem cell transplantation in adult patients treated using GRAFAPEX in combination with fludarabine as the preparative regimen.

    Do not begin the preparative regimen if the stem cell donor is not available. Monitor blood cell counts daily until hematopoetic recovery. Provide standard supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery.

    5.2 Seizures

    There have been reports of seizures in patients following treatment with treosulfan. Monitor patients for signs of neurological adverse reactions. Clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.

    5.3 Skin Disorders

    An increase of skin disorders (e.g. rash, dermatitis) was observed when patients received sodium bicarbonate-containing hydration in the course of treosulfan infusion, potentially because of acceleration of the pH‑dependent formation of alkylating epoxides [see Adverse Reactions ( 6.1) and Clinical Pharmacology ( 12.1)]. Keep skin clean and dry on days of GRAFAPEX infusion. Diaper dermatitis may occur because of excretion of treosulfan in the urine. Change diapers frequently during the 12 hours after each infusion of GRAFAPEX. Dermatitis may occur under occlusive dressings; change occlusive dressings after each infusion of GRAFAPEX.

    5.4 Injection Site Reactions and Tissue Necrosis

    GRAFAPEX may cause local tissue necrosis and injection site reactions, including erythema, pain, and swelling, in case of extravasation. Assure venous access patency prior to starting GRAFAPEX infusion, and monitor the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of GRAFAPEX. If extravasation occurs, stop the infusion immediately and manage medically as required. Do not administer by the intramuscular or subcutaneous routes.

    5.5 Secondary Malignancies

    There is an increased risk of a secondary malignancy with use of GRAFAPEX. Treosulfan is carcinogenic and genotoxic [see Nonclinical Toxicology ( 13.1)] .  

    The risk of secondary malignancy is increased in patients with Fanconi anemia and other DNA breakage disorders. The safety and efficacy of GRAFAPEX have not been established for patients with these disorders.

    5.6 Increased Early Morbidity and Mortality at Dosages Higher than Recommended

    In MC‑FludT.14/L Trial I (NCT00822393), 330 adult patients were randomized to treosulfan at 14 g/m 2/day (1.4 times the recommended dose) for three consecutive days or busulfan at 3.2 mg/kg/day for two days, in combination with fludarabine as a preparative regimen for allogeneic transplantation. This trial was discontinued early due to a higher incidence of early fatal and/or serious adverse reactions in patients receiving treosulfan. Avoid exceeding the recommended GRAFAPEX dosage of 10 g/m 2daily for three consecutive days.

    5.7 Embryo-Fetal Toxicity

    Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman because it is genotoxic and affects dividing cells [see Clinical Pharmacology ( 12) and Nonclinical Toxicology ( 13)]. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 6 months following the last dose of GRAFAPEX. Advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Use in Specific Populations ( 8.1) and ( 8.3)].

  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    • Myelosuppression [see Warnings and Precautions ( 5.1)]
    • Seizures [see Warnings and Precautions ( 5.2)]
    • Skin Disorders [see Warnings and Precautions ( 5.3)]
    • Injection Site Reactions and Tissue Necrosis [see Warnings and Precautions ( 5.4)]
    • Secondary Malignancies [see Warnings and Precautions ( 5.5)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    MC‑FludT.14/L Trial II

    The safety of GRAFAPEX was evaluated in 553 adult patients with AML and MDS in a randomized trial (MC‑FludT.14/L Trial II) comparing GRAFAPEX in combination with fludarabine to busulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation. The patients were randomized to receive GRAFAPEX (n=270) 10 g/m² daily on day -4, -3 and -2 or to busulfan (n=283) 0.8 mg/kg every 6 hours on day -4 and -3 in combination with fludarabine 30 mg/m 2daily on day -6, -5, -4, -3 and -2, and hematopoietic stem cell transplantation on day 0   [see Clinical Studies ( 14)] . 

    Fatal regimen-related adverse reactions occurred within 30 days of transplantation in 1.9% of patients on the GRAFAPEX arm. All fatalities were due to pulmonary adverse reactions.

    The most common adverse reactions (≥20%) in patients treated with GRAFAPEX were musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Selected Grade 3 or 4 nonhematological laboratory abnormalities were increased GGT, increased bilirubin, increased ALT, increased AST, and increased creatinine. 

    Table 3 shows the adverse reactions in Study MC‑FludT.14/L Trial II through transplant Day +30.

    Table 3: Adverse Reactions in ≥10% of Patients through Transplant Day +30 in Study MC-FludT.14/L Trial II
     Adverse Reaction*All GradesGrades 3 or 4
    GRAFAPEX(N = 270)Busulfan(N = 283)GRAFAPEX(N = 270)Busulfan(N = 283)
     % % % %
     Musculoskeletal pain 39 27 5 2
     Stomatitis 38 48 6 7
     Pyrexia 34 36 1 3
     Nausea 33 41 3 6
     Edema 29 18 0.7 1
     Infection 1 23 18 12 6
     Vomiting 22 19 1 1
     Rash 17 13 1 1
     Diarrhea 17 18 1 1
     Headache 16 18 1 1
     Febrile neutropenia 15 11 15 11
     Abdominal pain 15 13 3 2
     Hypertension 14 21 8 10
     Hemorrhage 14 14 1 1
     Fatigue 13 15 1 0.4
     Constipation 12 12 0.4 0
     Tachycardia 10 5 1 2
     Hepatotoxicity 10 8 4 3
    *Includes grouped terms
    1Includes fatalities: n=6 in the GRAFAPEX arm and n=2 in the busulfan arm
    Grading is based on Common Terminology Criteria for Adverse Events version 4.03

    Clinically relevant adverse reactions in <10% of patients who received GRAFAPEX included:

    Neoplasms benign, malignant and unspecified (including cysts and polyps): second malignancy
    Metabolism and nutrition disorders:
    Decreased appetite, impaired glucose tolerance
    Psychiatric disorders: Insomnia, confusional state, agitation
    Nervous system disorders: Paresthesia, dizziness
    Ear and labyrinth disorders: Vertigo
    Cardiac disorders: Cardiac failure, pericardial effusion
    Vascular disorders: Flushing, embolism, hypotension
    Respiratory, thoracic and mediastinal disorders: Pneumonitis, pleural effusion, pharyngeal or laryngeal inflammation, dyspnea, cough, oropharyngeal pain, hiccups, dysphonia
    Gastrointestinal disorders: Oral pain, gastritis, dyspepsia, dysphagia, abdominal distension, dry mouth
    Skin and subcutaneous tissue disorders: Palmar plantar erythrodysesthesia syndrome, pruritus, erythema, dermatitis, skin hyperpigmentation, dry skin
    Renal and urinary disorders: Acute kidney injury, hematuria, urinary tract pain
    General disorders and administration site conditions: Chills, pain

    Investigations: Weight decreased or increased, increase of C‑reactive protein

    All patients treated with GRAFAPEX and fludarabine developed neutropenia, anemia, and thrombocytopenia. One patient on the GRAFAPEX arm had graft failure. Table 4 summarizes the selected nonhematological laboratory abnormalities in Study MC-FludT.14/L Trial II by treatment arm through Day +30 posttransplant.

    Table 4. Selected Grades 3-4 Laboratory Abnormalities through Transplant Day +30 in Study MC-FludT.14/L Trial II
    Laboratory AbnormalityGRAFAPEX
    N = 270     %    		Busulfan
    N = 283     %

    Gamma Glutamyl Transferase Increased

    16

    28

    Bilirubin Increased

    6

    5

    Alanine Aminotransferase Increased

    6

    4

    Aspartate Aminotransferase Increased

    4

    1

    Creatinine Increased

    3

    0.7

    Grading is based on Common Terminology Criteria for Adverse Events version 4.03

    6.2 Postmarketing Experience

    The following additional adverse reactions have been identified during post approval use of GRAFAPEX in preparative regimens prior to hematopoietic stem cell transplantation in adult and pediatric patients in other countries. As these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Metabolism and Nutrition Disorders: Acidosis
    Nervous system disorders: Peripheral sensory neuropathy
    Renal and urinary disorders: Renal failure
    Immune system disorders: Hypersensitivity

  • 7 DRUG INTERACTIONS

    7.1 Effect of GRAFAPEX on Other Drugs

    Certain CYP2C19 and CYP3A4 Substrates

    Monitor for adverse reactions of certain CYP2C19 or CYP3A4 substrates where minimal concentration changes may lead to serious or life-threatening toxicities, and reduce the dosage, as needed, if recommended in the prescribing information of these substrates.

    Treosulfan is a CYP2C19 and CYP3A4 inhibitor [see Clinical Pharmacology ( 12)] . Concomitant use of GRAFAPEX is predicted to increase the exposure of CYP2C19 and CYP3A4 substrates based on a mechanistic understanding of treosulfan metabolism, which may increase the risk of their adverse reactions.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman because it is genotoxic and affects dividing cells [see Clinical Pharmacology ( 12) and Nonclinical Toxicology ( 13)] . There are no available human clinical data on the use of treosulfan in pregnant women to support an estimation of a drug-associated risk. Specific embryo-fetal developmental toxicity studies with treosulfan in animals were not conducted. Advise pregnant women of the potential risk to a fetus [see Data].

    In the U.S. general population, the estimated background risk of major birth defects is 2% – 4% and of miscarriage is 15% – 20% of clinically recognized pregnancies.

    Data

    Animal Data

    Animal reproductive or developmental toxicity studies were not conducted with treosulfan. Treosulfan is genotoxic and is toxic to dividing cells, suggesting it can cause embryotoxicity and teratogenicity.

    8.2 Lactation

    Risk Summary

    There is no data on the presence of treosulfan or its metabolites in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with GRAFAPEX and for 1 week after the last dose.

    8.3 Females and Males of Reproductive Potential

    Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1)].

    Pregnancy Testing

    Conduct pregnancy testing in females of reproductive potential within 7 days prior to initiating therapy with GRAFAPEX.

    Contraception

    Females

    Advise females of reproductive potential to use effective contraception during and up to 6 months after treatment with GRAFAPEX.

    Males

    Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Nonclinical Toxicology ( 13.1)]

    Infertility

    Based on findings in animal studies, GRAFAPEX can impair fertility in females and males, and may cause temporary or permanent infertility [see Nonclinical Toxicology ( 13.1)] .

    8.4 Pediatric Use

    The safety and efficacy of GRAFAPEX as part of a preparative regimen prior to allogeneic hematopoietic stem cell transplant in pediatric patients 1 year of age and older with AML or MDS have been established based on evidence from an adequate and well-controlled study in adults, with additional pharmacokinetic and safety data in 111 pediatric patients, including 22 infants (1 month to < 2 years), 54 children (2 to < 12 years), and 35 adolescents (12 to < 17 years) [see Adverse Reactions ( 6.1), Clinical Pharmacology ( 12.3), and Clinical Studies ( 14)] . The incidence of hepatic and gastrointestinal adverse reactions was higher in pediatric patients than in adults.

    Safety and effectiveness of GRAFAPEX as part of a preparative regimen prior to allogeneic hematopoietic stem cell transplant in pediatric patients with AML or MDS younger than 1 year of age have not been established.

    Juvenile Animal Toxicity Data

    Treatment of juvenile rats from postnatal day (PND) 10 to 35 with daily doses of 10, 50 or 100 mg/kg treosulfan (approximately 0.006, 0.03, 0.06-‑fold the human dose based on body surface area, BSA) generally resulted in findings comparable to those seen in adult animals. A delayed physical development indicated by decreased body weight, reduced relative organs weights, and delayed time point of vaginal opening were noted in the high-dosed rats. In a separate study, single intravenous administrations of 500 mg/kg treosulfan (0.3-‑fold the human dose based on BSA) to juvenile (PND 10) and young adult (PND 34 – 35) rats, treosulfan concentrations in brain tissue were low compared to plasma concentrations, but were approximately 2- to 3-fold higher in juvenile rats (4-6%) in comparison to young adults (2-3%).

    8.5 Geriatric Use

    Of the total number of GRAFAPEX-treated patients with AML or MDS in Study MC-FludT.14/L Trial II (n=270), 73 (27%) were 65 to 74 years of age, and none were 75 years of age and older [see Clinical Studies ( 14)] . No significant differences in safety or effectiveness were observed between these subjects and younger subjects.

  • 10 OVERDOSAGE

    The principal toxic effect of treosulfan in cases of overdose are myeloablation and prolonged pancytopenia, mucositis, skin toxicity, nausea, vomiting and gastritis. In case of overdosage, monitor blood counts frequently and provide vigorous supportive measures as medically indicated.

  • 11 DESCRIPTION

    GRAFAPEX for injection contains treosulfan, an alkylating drug. Treosulfan is known chemically as L-‑threitol ‑1,4-‑dimethanesulfonate. Treosulfan is soluble in water (7% m/v) at 25ᴼC. Treosulfan is not hygroscopic.Treosulfan has the molecular formula C 6H 14O 8S 2and a molecular weight of 278.3 g/mole. Treosulfan has the following chemical structure:

    Treosulfan Chemical Structure

    GRAFAPEX is intended for intravenous administration. It is supplied as a white, sterile, lyophilized powder for injection in glass vials containing 1 g or 5 g treosulfan.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Treosulfan is an alkylating agent. DNA alkylation is thought to be responsible for the cytotoxic activities of treosulfan. Treosulfan showed hematopoietic stem cell depleting activity as well as immunosuppressive and antitumor activity in mouse models of leukemia.

    12.2 Pharmacodynamics

    Increase in treosulfan exposure was associated with an increased incidence of infection-related death. Treosulfan time course of pharmacodynamic response is unknown.

    12.3 Pharmacokinetics

    Treosulfan pharmacokinetic parameters were observed at the approved recommended dosage, unless otherwise specified.

    Treosulfan is a prodrug. Treosulfan mean ± SD area under the curve (AUC) is 1,200 ± 211 hr mcg/mL. There was no dose accumulation.

    Distribution

    Treosulfan mean (CV%) volume of distribution is approximately 41 liters (CV%: 19%). Treosulfan does not bind to plasma albumin.

    Elimination

    Treosulfan mean (± standard deviation) terminal half-life is 1.7 ± 0.4 hours.

    Metabolism

    The pharmacologically inactive treosulfan is converted spontaneously under physiological conditions into the active monoepoxide intermediate (2S,3S)‑1,2‑epoxybutane‑3,4‑diol‑4‑methanesulfonate) and finally to active L‑diepoxibutane (2S,3S)‑1,2:3,4‑diepoxybutane).

    Excretion

    A median of 42% of the treosulfan dose is excreted unchanged in the urine within 24 hours, and 89% of this unchanged fraction is excreted within the first 8 hours after administration.

    Specific Populations

    No clinically significant differences in the pharmacokinetics of treosulfan based on sex, mild renal impairment (CLcr 60‑89 mL/min), or mild hepatic impairment (total bilirubin less than or equal to ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST). The effect of moderate or severe renal impairment, moderate or severe hepatic impairment, and age ≥ 65 years on treosulfan pharmacokinetics is unknown.

    Pediatric Patients

    Treosulfan exposure in pediatric patients with BSA < 0.7 m 2and with BSA 0.7 to < 1.1 m 2are 11% and 5% higher, respectively, compared to adults.

    No clinically significant difference in treosulfan median terminal half‑life was observed between pediatric patients and adults. The median terminal half‑life of the active monoepoxide intermediate was 1.6 hrs in pediatric patients.

    Drug Interaction Studies

    In Vitro Studies

    CYP Enzymes:Treosulfan is a CYP2D6 substrate and its monoepoxide intermediate is a CYP2C8 substrate. Treosulfan inhibits CYP2C19 and CYP3A4 (using midazolam as substrate), but does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, or CYP3A4 (using testosterone as substrate).

    Transporter Systems: Treosulfan does not inhibit BCRP, BSEP, MATE1, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, or OCT2.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis and Mutagenesis

    No carcinogenicity study has been conducted. Treosulfan was mutagenic in the in vitro bacterial mutagenicity assay (Ames test) and clastogenic in the in vitro micronucleus assay in human lymphocytes.

    No dedicated animal fertility studies were conducted. In a general toxicity study in rats, animals were treated with 5 or 50 mg/kg/day treosulfan orally for 7 months, 6 days a week. Spermatogenesis and ovarian function were significantly affected, starting at 5 mg/kg (0.003‑fold the human dose based on BSA). Findings included reduced weight of the testicles, seminal vesicle, prostate, and uterus, as well as spermatogenesis reduction and arrest, uterine atrophy, and reduced or absent corpora lutea and follicles. 

  • 14 CLINICAL STUDIES

    The efficacy of GRAFAPEX was evaluated in a randomized active-controlled trial (MC‑FludT.14/L Trial II; NCT00822393) comparing GRAFAPEX to busulfan in combination with fludarabine as a preparative regimen for allogeneic transplantation. Eligible patients included adults 18 to 70 years old with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Karnofsky performance status > 60%, and age ≥ 50 years or hematopoietic cell transplantation comorbidity index [HCT‑CI] score > 2. Patients were excluded if the creatinine clearance was < 60 mL/min, forced expiratory volume (FEV1) < 50% or on supplemental oxygen, left ventricular ejection fraction (LVEF) < 40%, bilirubin > 3X ULN, or aminotransferases (ALT or AST) > 5X ULN.

    The patients were randomized to receive GRAFAPEX 10 g/m² daily on day -4, -3 and -2 or to busulfan 0.8 mg/kg every 6 hours on day -4 and -3 in combination with fludarabine 30 mg/m 2daily on day -6, -5, -4, -3 and -2, and hematopoietic stem cell transplantation on day 0. For the subset of patients with unrelated donors, antithymocyte globulin was administered in 97% and 95% of patients on each arm, respectively. Cyclosporine and methotrexate was used as graft‑vs‑host disease prophylaxis.

    There were 570 patients randomized to GRAFAPEX (n = 280) or busulfan (n = 290). The efficacy population included 365 patients with AML and 205 patients with MDS: 536 patients received peripheral blood stem cells, 15 patients received marrow stem cells, and 19 patients were not transplanted. Table 5 shows the baseline characteristics of the study patients. 

    Table 5: Baseline characteristics of the study patients (MC‑FludT.14/L Trial II)
    Baseline CharacteristicsGRAFAPEX (n = 280)Busulfan (n = 290)

    Age, median (range), years

    60.0 (37, 70)

    60.5 (31, 70)

    Age, n (%)

    • 18-64 years
    • 65-70 years


    204 (73%)

    76 (27%)

    218 (75%)

    72 (25%)

    Gender, n (%)

    • Male
    • Female

    171 (61%) 
    109 (39%)

    176 (61%)
    114 (39%)

    Weight, median (range), kg

    80.0 (48.0, 144.0)

    78.1 (46.0, 141.9)

    Disease, n (%)

        AML

        MDS

    192 (69%)

    88 (31%)

    173 (60%)

    117 (40%)

    AML remission status, n (%)

    • CR1
    • >CR1

    164 (85%)

    28 (15%)

    148 (86%)

    25 (14%)
    MDS risk group, n (%)
    • Lower risk
    • Higher risk

    20 (23%)

    68 (77%)

    20 (17%)

    97 (83%)

    HCT‑CI score

    • ≤2
    • >2

    116 (41%)

    164 (59%)

    118 (41%)

    172 (59%)

    Donor

    • Matched related
    • Matched unrelated

    66 (24%)

    214 (76%)

    68 (23%)

    222 (77%)

    Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CR1: complete remission 1; HCT-CI: hematopoietic cell transplant-specific comorbidity index

    Efficacy was established on the basis of overall survival (OS), defined as the time from randomization until death from any cause. The hazard ratio (HR) for OS (stratified by donor type and risk group) compared to busulfan was 0.67 (95% CI: 0.51, 0.90) in the randomized population, 0.73 (95% CI: 0.51, 1.06) in patients with AML, and 0.64 (95% CI: 0.40, 1.02) in patients with MDS. Results are displayed in Figures 1, 2, and 3 below.

    Figure 1:       Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II

    Figure 1

    Figure 2:       Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II (patients with AML)

    Figure 2

    Figure 3:       Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II (patients with MDS)

    Figure 3

  • 15 REFERENCES

    1. “OSHA Hazardous Drugs.” OSHA.  http://www.osha.gov/SLTC/hazardousdrugs/index.html

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    GRAFAPEX (treosulfan) for injection is a white, sterile, lyophilized powder for reconstitution. It is supplied in a carton containing one single-dose vial.  

    Presentation

    NDC

    1 g/vial

    59137-335-01

    5 g/vial

    59137-365-01

    Storage and Handling

    Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. (Excursions permitted between 15°C and 30°C)

    GRAFAPEX is a hazardous drug. Follow applicable special handling and disposal procedures 1.

  • 17 PATIENT COUNSELING INFORMATION

    Infections

    • Inform patients of the increased risk of infections after treatment with GRAFAPEX that may require antibiotic, antiviral, or antifungal treatment and hospitalization.
    • Advise patients to contact their healthcare provider immediately in case of any new or worsening signs of infection, e.g., cough, headache, diarrhea, or fever [see Warnings and Precautions ( 5.1)] .

    Seizures

    • Inform patients that seizures may occur [see Warnings and Precautions ( 5.2)] .

    Skin Disorders

    • Advise patients to clean “sweaty” skin parts (armpit, groin, genital area, inframammary line), each with a disposable washcloth and clear water.
    • Advise patients not to apply any cream to the skin on the days of chemotherapy, and clothing should not be too tight, in order to let the skin “breathe” [see Warnings and Precautions ( 5.3)] .

    Secondary Malignancies

    • Inform patients of the possible risk of a second malignancy [see Warnings and Precautions ( 5.5)] .

    Embryo-Fetal Toxicity

    • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations ( 8.1)] .
    • Advise females of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 6 months following the last dose of GRAFAPEX [see Warnings and Precautions ( 5.7) and Use in Specific Populations ( 8.3)] .
    • Advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Warnings and Precautions ( 5.7) and Use in Specific Populations ( 8.3)] .

    Lactation

    • Advise women not to breastfeed during treatment with GRAFAPEX and for 1 week after the last dose [see Use in Specific Populations ( 8.2)].

    Infertility

    • GRAFAPEX can impair fertility in females and males, and may cause temporary or permanent infertility [see Use in Specific Populations ( 8.3)] .

    Manufactured for:
    Medexus Pharma, Inc.
    Chicago, Illinois 60606
    USA

    GRAFAPEX™ is a trademark of medac GmbH, Germany.

  • PRINCIPAL DISPLAY PANEL - GRAFAPEX™ 1 g

    Carton Label - GRAFAPEX™ 1 g

    NDC 59137- 335-01

    GRAFAPEX™
    (treosulfan) for injection
    1 g/vial

    For intravenous infusion
    after reconstitution

    WARNING: Hazardous Drug 

    One Single-dose Vial.
    Discard Unused Portion.

    Rx only

    Grafapex 1g Carton

    One Single-dose Vial

    Vial Label - GRAFAPEX™ 1 g

    NDC59137 -335-00

    GRAFAPEX™
    (treosulfan)
    for injection
    1 g/vial

    For intravenous infusion
    after reconstitution

    WARNING: Hazardous Drug

    Single-dose Vial.
    Discard Unused Portion.

    Recommended dosage: See Prescribing
    Information. Store at 20°C to 25°C (68°F to
    77°F) [see USP Controlled Room Temperature].
    Do not use if solution contains a precipitate.

    Rx only

    Manufactured for: Medexus Pharma, Inc.
    Chicago, IL 60606 USA

    Manufactured by: 
    Oncotec Pharma Produktion GmbH,
    Dessau-Roβlau,
    Germany

    Grafapex 1g Vial

  • PRINCIPAL DISPLAY PANEL - GRAFAPEX™ 5 g

    Carton Label - GRAFAPEX™ 5 g

    NDC59137- 365-01

    GRAFAPEX™
    (treosulfan) for injection
    5 g/vial

    For intravenous infusion
    after reconstitiution

    WARNING: Hazardous Drug

    One Single-dose Vial.
    Discard Unused Portion.

    Rx only

    Grafapex 5g Carton

    Vial Label - GRAFAPEX™ 5 g

    NDC59137- 365-00
    GRAFAPEX™
    (treosulfan)
    for injection
    5 g/vial

    For intravenous infusionafter reconstitution

    WARNING: Hazardous Drug

    Single-dose Vial.
    Discard Unused Portion.

    Recommended dosage: See Prescribing
    Information. Store at 20°C to 25°C (68°F to
    77°F) [see USP Controlled Room Temperature].
    Do not use if solution contains a precipitate.

    Rx only

    Manufactured for: Medexus Pharma, Inc.
    Chicago, IL 60606 USA

    Manufactured by:
    Oncotec Pharma Produktion GmbH,
    Dessau-Roβlau, Germany

    Grafapex 5g Vial

  • INGREDIENTS AND APPEARANCE
    GRAFAPEX 
    treosulfan injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 59137-335
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TREOSULFAN (UNII: CO61ER3EPI) (TREOSULFAN - UNII:CO61ER3EPI) TREOSULFAN1000 mg  in 1 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 59137-335-011 in 1 CARTON01/28/2025
    11 g in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21475901/28/2025
    GRAFAPEX 
    treosulfan injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 59137-365
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TREOSULFAN (UNII: CO61ER3EPI) (TREOSULFAN - UNII:CO61ER3EPI) TREOSULFAN5000 mg  in 5 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 59137-365-011 in 1 CARTON01/28/2025
    15 g in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21475901/28/2025
    Labeler - Medexus Pharma, Inc. (078811131)
    Establishment
    NameAddressID/FEIBusiness Operations
    Oncotec Pharma Produktion GmbH366308617manufacture(59137-335, 59137-365) , analysis(59137-335, 59137-365)

    • Trademark Results [GRAFAPEX]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    GRAFAPEX
    GRAFAPEX
    98888869 not registered Live/Pending
    medac Gesellschaft für klinische Spezialpräparate mbH
    2024-12-06
    GRAFAPEX
    GRAFAPEX
    90491908 not registered Live/Pending
    medac Gesellschaft für klinische Spezialpräparate mbH
    2021-01-27
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.